Inclusion Criteria:

          -  Male or female subjects aged >/=21 years

          -  Dose escalation phase: Subjects with histologically or cytologically confirmed
             advanced malignancies (solid tumors and malignant lymphomas) who were refractory to or
             had exhausted all available therapies. Subjects had to have evaluable or measurable
             disease (as per RECIST 1.1 or Cheson 2007 criteria).

          -  Expansion phase only: Subjects with advanced, histologically or cytologically
             confirmed gastric cancer, triple negative breast cancer (TNBC), or diffuse large
             B-cell lymphoma (DLBCL), who were refractory to or had exhausted all available
             therapies. Subjects had to have evaluable or measurable disease (as per RECIST 1.1 or
             Cheson 2007 criteria).

          -  Archival tumor tissue to conduct molecular and / or genetic studies must be collected
             from all study subjects enrolled in this study.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          -  Life expectancy of at least 12 weeks

          -  Adequate bone marrow, liver, and renal functions as assessed by laboratory analysis to
             be conducted within 7 days prior to the first dose of study drug

          -  International normalized ratio (INR) and partial thromboplastin time (PTT) </=1.5
             times ULN (upper limit of normal)

        Exclusion Criteria:

          -  Known hypersensitivity to the study drug or excipients of the preparation or any agent
             given in association with this study

          -  History of cardiac disease including congestive heart failure > New York Heart
             Association (NYHA) Class II, unstable angina (anginal symptoms at rest) or new-onset
             angina (within the last 6 months) or myocardial infarction within the past 6 months
             and cardiac arrhythmias requiring anti-arrhythmic therapy except for beta-blockers and
             digoxin; evidence for uncontrolled coronary artery disease (e.g. angina pectoris,
             myocardial infarction within 6 months prior to study entry, major regional wall motion
             abnormalities upon baseline echocardiography)

          -  Previous pulmonary embolism within 12 months prior to study entry

          -  Uncontrolled hypertension defined as systolic blood pressure >150 mmHg or diastolic
             blood pressure >90 mmHg on 2 or more consecutive blood pressure readings, despite
             optimal medical management

          -  Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Chronic or active hepatitis B or C, requiring antiviral therapy

          -  Active clinically serious infections of > Grade 2 and/or active infections that
             require treatment with systemic agent

          -  Uncontrolled seizure disorder requiring therapy (such as steroids or anti-epileptics
             with significant CYP interaction)

          -  Evidence or history of bleeding disorder, i.e. any hemorrhage / bleeding event of >
             Grade 2 within 4 weeks prior to the first dose of study drug